INSCRIPTA® ACQUIRES INFINOME BIOSCIENCES AND SESTINA BIO TO ADVANCE SUSTAINABLE BIOMANUFACTURING
January 18, 2023
With the addition of Infinome and Sestina Bio, Inscripta adds to its portfolio of cutting-edge technologies for biomanufacturing products for…
Read More
Sestina Bio uses Inscripta's ONYX® Platform to develop microbial strain ready for scale-up in less than 12 months
October 5, 2022
Inscripta and Sestina Bio announced successful development of a ready-to-scale microbial strain producing Bakuchiol, a natural retinol…
Read More
KALSEC® PARTNERS WITH INFINOME™ BIOSCIENCES TO SUSTAINABLY DEVELOP AND MANUFACTURE PRECISION FERMENTATION PRODUCTS
August 10, 2022
Through advanced technology and processes, Infinome is creating sustainable manufacturing solutions for Kalsec.…
Read More
Willow Biosciences Incorporates Inscripta's Onyx® Platform to Expand Strain Engineering Capabilities and Throughput
June 6, 2022
Willow Biosciences Inc., a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable…
Read More
Aldevron Licenses the Manufacturing of MAD7, a Type-V CRISPR Nuclease From Inscripta
May 16, 2022
A partnership between two CRISPR pioneers will provide the global scientific community with GMP MAD7™ Nuclease…
Read More
Ginkgo Bioworks Adopts Inscripta®’s Onyx® Digital Genome Engineering Platform to Continue Accelerating its Genome Editing Throughput
January 10, 2022
Inscripta®, the Digital Genome Engineering Company, today announced that Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell…
Read More
Inscripta® Appoints Kristala Prather, PhD to its Board of Directors
January 5, 2022
Inscripta adds a distinguished MIT Professor and synthetic biology pioneer, Dr. Kristala Prather, to the Board of Directors.
Read More
Hunterian Medicine® Licenses Inscripta’s MAD7™ Nuclease to Advance Gene Editing Research and Development
October 12, 2021
Inscripta and Hunterian pioneer new program to provide access to novel CRISPR enzymes for biotherapeutic development…
Read More
Amyris Partners with Inscripta® to Enhance Development of Sustainable Ingredients Using the Onyx® Genome Engineering Platform
October 5, 2021
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer…
Read More
Inscripta® Announces the First Commercial Shipment of Its Onyx® Digital Genome Engineering Platform and Closes $150 Million in New Financing
April 5, 2021
GeneMill at the University of Liverpool receives first benchtop Onyx platform in EuropeFinancing round led by Fidelity and T. Rowe Price funds…
Read More
